이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Citius Pharmaceuticals 관리

관리 기준 확인 2/4

Citius Pharmaceuticals' CEO는 Leonard Mazur, Mar2016 에 임명되었습니다 의 임기는 8.42 년입니다. 총 연간 보상은 $ 1.98M, 24% 로 구성됩니다. 24% 급여 및 76% 보너스(회사 주식 및 옵션 포함). 는 $ 6.18M 가치에 해당하는 회사 주식의 5.67% 직접 소유합니다. 6.18M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 8.3 년입니다.

주요 정보

Leonard Mazur

최고 경영자

US$2.0m

총 보상

CEO 급여 비율	24.0%
CEO 임기	8.6yrs
CEO 소유권	5.7%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	8.5yrs

최근 관리 업데이트

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18

CEO 보상 분석

Leonard Mazur 의 보수는 Citius Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$40m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	n/a	n/a	-US$39m
Sep 30 2023	US$2m	US$475k	-US$34m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	n/a	n/a	-US$28m
Sep 30 2022	US$1m	US$400k	-US$34m
Jun 30 2022	n/a	n/a	-US$31m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	n/a	n/a	-US$26m
Sep 30 2021	US$788k	US$348k	-US$25m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	n/a	n/a	-US$21m
Sep 30 2020	US$550k	US$250k	-US$18m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	n/a	n/a	-US$16m
Sep 30 2019	US$473k	US$250k	-US$16m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$13m
Sep 30 2018	US$398k	US$250k	-US$13m

보상 대 시장: Leonard 의 총 보상 ($USD 1.98M )은 US 시장( $USD 680.04K ).

보상과 수익: 회사가 수익성이 없는 동안 Leonard 의 보상이 증가했습니다.

CEO

Leonard Mazur (79 yo)

8.6yrs

테뉴어

US$1,981,113

보상

Mr. Leonard L. Mazur is Chairman, Chief Executive Officer & President of Citius Oncology, Inc. from August 12, 2024. Mr. Mazur has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Leonard Mazur	Co-Founder	8.6yrs	US$1.98m	5.67% $ 4.5m
Myron Holubiak	Co-Founder & Executive Vice Chairman	9yrs	US$1.59m	1.1% $ 864.6k
Myron Czuczman	Executive VP & Chief Medical Officer	4.3yrs	US$1.17m	0% $ 0
Jaime Bartushak	Chief Business Officer	6.9yrs	US$809.00k	0.033% $ 26.2k
Gary Talarico	Executive Vice President of Operations	8.6yrs	데이터 없음	데이터 없음
Ilanit Allen	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Alan Lader	Senior VP and Head of Clinical Operations & Quality Assurance	2.7yrs	데이터 없음	데이터 없음
Dhananjay Wadekar	Senior Vice President of Business Strategy	3.8yrs	데이터 없음	데이터 없음
Kelly Creighton	Executive Vice President of Chemistry	2.9yrs	데이터 없음	데이터 없음
Nikolas Burlew	Executive Vice President of Quality Assurance	1.8yrs	데이터 없음	데이터 없음
Catherine Kessler	Executive Vice President of Regulatory Affairs	1.1yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 관리: CTXR 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Leonard Mazur	Co-Founder	10.1yrs	US$1.98m	5.67% $ 4.5m
Myron Holubiak	Co-Founder & Executive Vice Chairman	9yrs	US$1.59m	1.1% $ 864.6k
Dennis McGrath	Independent Director	1.7yrs	US$150.13k	0% $ 0
Michael Matthay	ARDS Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Suren Dutia	Independent Director	9yrs	US$196.97k	0% $ 0
Carol Webb	Independent Director	8.6yrs	US$190.97k	0.0066% $ 5.1k
Eugene Holuka	Independent Director	8.3yrs	US$190.97k	0.0013% $ 1.0k
Issam Raad	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mark Rupp	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Leonard Mermel	Member of Scientific Advisory Board	6.3yrs	데이터 없음	데이터 없음
John Laffey	ARDS Scientific Advisory Board Member	3.3yrs	데이터 없음	데이터 없음
Lorraine Ware	ARDS Scientific Advisory Board Member	no data	데이터 없음	데이터 없음

8.5yrs

평균 재임 기간

77yo

평균 연령

경험이 풍부한 이사회: CTXR 의 이사회는 경험(평균 재직 기간 8.3 년)으로 간주됩니다.

Citius Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New major risk - Financial position

New minor risk - Profitability

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

New minor risk - Share price stability

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Price target decreased by 21% to US$3.17

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Consensus EPS estimates fall by 24%

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Forecast breakeven date pushed back to 2025

Price target increased by 25% to US$5.00

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Price target decreased to US$3.60

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals GAAP EPS of -$0.06

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Price target increased to US$4.00

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Critical Care Biopharma - Citius Pharmaceuticals

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius: 2022 Is A Year Of Catalysts

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Citius: Halt For Superiority On The Horizon

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar